Liver transplantation for hepatitis C.

Area of Science:

• Hepatology
• Transplant Surgery
• Virology

Background:

• Hepatitis C virus (HCV) infection is a primary cause of end-stage liver disease globally.
• HCV recurrence post-liver transplantation affects nearly all patients, leading to graft cirrhosis in 30% within 5 years.
• Optimal immunosuppression strategies to prevent accelerated HCV progression in transplant recipients remain unclear.

Purpose of the Study:

• To evaluate the effectiveness of a steroid-free immunosuppression protocol combined with preemptive antiviral therapy for preventing Hepatitis C virus recurrence after liver transplantation.
• To describe the experience with living-donor liver transplantation for Hepatitis C patients at Osaka University.

Main Methods:

• Review of international transplant center reports on Hepatitis C virus management post-liver transplantation.
• Implementation of a steroid-free immunosuppression regimen.
• Preemptive combination therapy using low-dose interferon and ribavirin.

Main Results:

• Steroid-free immunosuppression and preemptive interferon/ribavirin therapy are considered the best strategy for managing Hepatitis C virus infection in liver transplant recipients.
• Experience at Osaka University with living-donor liver transplantation for Hepatitis C patients is presented.

Conclusions:

• A standardized approach to managing Hepatitis C virus infection in liver transplant recipients is necessary.
• Collaborative efforts among international liver transplant centers are crucial for standardizing treatment protocols.